Venture

Venture: UOB Kay Hian has results preview. House expect 4Q12 results to be in line with expectations. Prospects for 2013 look promising due to a new life science customer and several new product launches in 2H13. Revenue growth and margins are expected to be stronger in 2H13 due to contributions from new products and an improvement in product mix. Add that 1H13 is expected to be seasonally softer. Venture is expected to ramp up production in 2H13. 2013 is expected to be backend loaded. Rev growth and margins are expected to be stronger in 2H13 due to contribution from new products and an improvement in product mix. Overall, house maintain BUY with $9.03 TP.